{"id":"W2755831795","doi":"10.1016/j.jaad.2017.06.153","title":"Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3)","year":2017,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":113,"is_retracted":false,"has_abstract":true,"ca_institutions":"Queen's University; SKiN Health","funders":"Eli Lilly and Company","keywords":"Ixekizumab; Medicine; Plaque psoriasis; Psoriasis; Randomized controlled trial; Clinical trial; Dermatology; Internal medicine; Secukinumab; Psoriatic arthritis","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001332917,0.0002969237,0.004815313,0.000124873,0.0002398651,0.000007180266,0.0007656904,0.0003083358,0.000009959872],"category_scores_gemma":[0.00219497,0.0001459442,0.001586565,0.00009272518,0.00221094,0.00009419271,0.00009170488,0.0002584719,0.00000113645],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002902912,"about_ca_system_score_gemma":0.0002226343,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007874512,"about_ca_topic_score_gemma":0.000005774921,"domain_scores_codex":[0.9945543,0.001768052,0.003037231,0.0002396099,0.0001187267,0.0002820539],"domain_scores_gemma":[0.9819274,0.008459236,0.008926509,0.0004492432,0.0001931823,0.00004443687],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.962324,0.001501565,0.000174488,0.00002317605,0.007905689,0.000003436128,0.00087727,0.00004848068,0.002969886,0.0003352719,0.0007291554,0.02310763],"study_design_scores_gemma":[0.9503307,0.005016904,0.001379113,0.0001160828,0.004189856,0.0003625915,0.0002693383,0.00002846009,0.0344488,0.0004559694,0.003269485,0.0001327476],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9836709,0.004392588,0.000333271,0.007775354,0.0008450844,0.002544139,0.0003352956,0.000003852917,0.00009946139],"genre_scores_gemma":[0.9910699,0.008032365,0.0004672674,0.0001205009,0.0001196341,0.00006033107,0.000004413207,0.00001605549,0.0001095682],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03147891,"threshold_uncertainty_score":0.81463,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04825524568326119,"score_gpt":0.3700946110253621,"score_spread":0.3218393653421009,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}